Onco Wiki / Disease

Adult granulosa cell tumor of the ovary

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

IDDIS-GRANULOSA-CELL
TypeDisease
Aliases
AGCTAdult granulosa cell tumorGCT ovaryadult-type GCTgranulosa cell tumorДоросла гранульозоклітинна пухлина яєчника
Statusreviewed 2026-05-04 | pending_clinical_signoff
DiseasesNone declared
SourcesSRC-ESMO-OVARIAN-2024 SRC-NCCN-OVARIAN-2025

Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.

Source YAML

icd_o_3_morphology8620/3
icd_o_3_topography["C56"]
icd_10C56
who_classificationWHO Classification of Female Genital Tumours 5th ed (2020): Adult granulosa cell tumour

Capabilities

Notes

Adult GCT is defined molecularly by the FOXL2 p.C134W mutation (present in ~97% of cases), which is the only pathognomonic molecular alteration in any solid tumor. FOXL2 is a granulosa cell transcription factor; the C134W mutation is a dominant-negative gain-of-function that prevents normal granulosa cell differentiation. Clinically, tumors present with estrogen excess (abnormal uterine bleeding, endometrial pathology) or abdominal mass. Prognosis is generally favorable for stage I (90% 10-yr OS) but late recurrences (10–20 years) are characteristic. No FDA-approved targeted therapy as of 2026; FOXL2 inhibition and CDK4/6 inhibitors are in clinical trials. FOXL2 mutation testing is diagnostic, not therapeutic selection (ESCAT IIB — clinical utility as diagnostic/prognostic marker).

Used By

Actionability

Algorithms

Disease

Indication

Questionnaires